

Steven A Rosenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6673424/publications.pdf>

Version: 2024-02-01

191
papers

39,817
citations

4658
85
h-index

3915
177
g-index

193
all docs

193
docs citations

193
times ranked

26599
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. <i>Journal of Clinical Oncology</i> , 2022, 40, 1741-1754.	1.6	65
2	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. <i>Science</i> , 2022, 375, 877-884.	12.6	156
3	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. <i>Cancer Cell</i> , 2022, 40, 479-493.e6.	16.8	64
4	Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-“PD-1 Naïve and Experienced Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3042-3052.	7.0	18
5	Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2112-2119.	27.0	207
6	Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 2469-2473.	1.3	6
7	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 932-946.	3.4	52
8	Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells. <i>Journal of Immunotherapy</i> , 2021, 44, 1-8.	2.4	21
9	A machine learning model for ranking candidate HLA class I neoantigens based on known neopeptides from multiple human tumor types. <i>Nature Cancer</i> , 2021, 2, 563-574.	13.2	38
10	Identification and Validation of T-cell Receptors Targeting <i>RAS</i> Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5084-5095.	7.0	26
11	Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. , 2021, 9, e002595.		31
12	Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. , 2021, 9, e002882.		13
13	Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 5289-5298.	7.0	39
14	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	15
15	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. <i>Blood</i> , 2021, 138, 3837-3837.	1.4	8
16	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3805-3815.	1.6	129
17	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
18	Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. <i>Cancer Cell</i> , 2020, 38, 454-472.	16.8	190

#	ARTICLE	IF	CITATIONS
19	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	12.6	273
20	High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12826-12835.	7.1	68
21	Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells. <i>Journal of Immunology</i> , 2020, 205, 539-549.	0.8	14
22	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. , 2020, 8, e000210.		27
23	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. <i>Nature Communications</i> , 2020, 11, 896.	12.8	98
24	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. <i>Clinical Cancer Research</i> , 2020, 26, 1267-1276.	7.0	69
25	mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 5976-5988.	8.2	218
26	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. <i>Blood</i> , 2020, 136, 50-51.	1.4	14
27	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1985-1992.e10.	0.7	6
28	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2019, 7, 1824-1836.	3.4	40
29	Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. <i>Nature Communications</i> , 2019, 10, 449.	12.8	118
30	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 534-543.	3.4	100
31	Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. <i>Cancer Discovery</i> , 2019, 9, 1022-1035.	9.4	184
32	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. <i>Journal of Immunology</i> , 2019, 202, 3458-3467.	0.8	36
33	BRAF Inhibition: Bridge or Boost to T-cell Therapy?. <i>Clinical Cancer Research</i> , 2019, 25, 2682-2684.	7.0	5
34	Tumor-infiltrating human CD4 ⁺ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. <i>Science Immunology</i> , 2019, 4, .	11.9	152
35	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1109-1114.	8.2	193
36	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. <i>Journal of Clinical Investigation</i> , 2019, 129, 4992-5004.	8.2	107

#	ARTICLE	IF	CITATIONS
37	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. <i>Journal of Immunotherapy</i> , 2018, 41, 241-247.	2.4	40
38	An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. <i>Molecular Therapy</i> , 2018, 26, 379-389.	8.2	78
39	Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	168
40	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. <i>JCI Insight</i> , 2018, 3, .	5.0	110
41	Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 10, 371-378.	4.1	24
42	T-cell Responses to TP53 Hotspot Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5562-5573.	7.0	114
43	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. <i>Nature Medicine</i> , 2018, 24, 724-730.	30.7	637
44	LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. <i>Cancer Research</i> , 2017, 77, 1880-1891.	0.9	44
45	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 947-951.	1.5	26
46	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <i>Nature Immunology</i> , 2017, 18, 255-262.	14.5	361
47	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. <i>Science</i> , 2017, 356, 200-205.	12.6	327
48	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 792-802.	10.7	203
49	A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 351-362.	7.0	52
50	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Molecular Therapy</i> , 2017, 25, 2245-2253.	8.2	227
51	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. <i>Clinical Cancer Research</i> , 2017, 23, 2491-2505.	7.0	158
52	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 135-141.	1.5	24
53	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	1.6	204
54	A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. <i>Human Gene Therapy Methods</i> , 2016, 27, 209-218.	2.1	48

#	ARTICLE	IF	CITATIONS
55	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2255-2262.	27.0	1,033
56	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2389-2397.	1.6	293
57	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5480-5486.	7.0	84
58	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. <i>Cancer Immunology Research</i> , 2016, 4, 669-678.	3.4	117
59	Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. <i>Cancer Immunology Research</i> , 2016, 4, 734-743.	3.4	163
60	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. <i>Nature Medicine</i> , 2016, 22, 433-438.	30.7	721
61	Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. <i>Molecular Therapy</i> , 2016, 24, 1078-1089.	8.2	51
62	Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 218-218.	1.4	98
63	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. <i>Journal of Clinical Investigation</i> , 2015, 125, 3981-3991.	8.2	328
64	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 2278-2288.	7.0	310
65	Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. <i>Journal of Virology</i> , 2015, 89, 6685-6694.	3.4	95
66	CCR 20th Anniversary Commentary: Autologous T Cellsâ€”The Ultimate Personalized Drug for the Immunotherapy of Human Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5409-5411.	7.0	7
67	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1â€”Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. <i>Clinical Cancer Research</i> , 2015, 21, 1019-1027.	7.0	677
68	Adoptive Cell Therapyâ€”Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. <i>Seminars in Oncology</i> , 2015, 42, 626-639.	2.2	76
69	Adoptive cell transfer as personalized immunotherapy for human cancer. <i>Science</i> , 2015, 348, 62-68.	12.6	1,911
70	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. <i>Molecular Therapy</i> , 2015, 23, 1380-1390.	8.2	88
71	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , 2015, 350, 1387-1390.	12.6	639
72	Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. <i>Clinical Cancer Research</i> , 2015, 21, 4431-4439.	7.0	147

#	ARTICLE	IF	CITATIONS
73	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. <i>Clinical Cancer Research</i> , 2015, 21, 534-543.	7.0	47
74	Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2015, 126, 2042-2042.	1.4	4
75	Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy. <i>Blood</i> , 2015, 126, 4426-4426.	1.4	14
76	Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 684-684.	1.4	35
77	Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 99-99.	1.4	4
78	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2246-2259.	8.2	892
79	Somatic Mutation of GRIN2A in Malignant Melanoma Results in Loss of Tumor Suppressor Activity via Aberrant NMDAR Complex Formation. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2390-2398.	0.7	26
80	Why is sentinel lymph node biopsy 'standard of care' for melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 245-246.	27.6	16
81	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. , 2014, 2, 25.		112
82	Pancreatic cancer. <i>Onc Immunology</i> , 2014, 3, e29194.	4.6	10
83	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 452-460.	0.7	20
84	Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. <i>Science</i> , 2014, 344, 641-645.	12.6	1,460
85	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. <i>Clinical Cancer Research</i> , 2014, 20, 3401-3410.	7.0	364
86	Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. <i>Human Pathology</i> , 2014, 45, 259-267.	2.0	30
87	IL-2: The First Effective Immunotherapy for Human Cancer. <i>Journal of Immunology</i> , 2014, 192, 5451-5458.	0.8	970
88	Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 550-550.	1.4	26
89	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3008-LBA3008.	1.6	6
90	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3008-LBA3008.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer. PLoS ONE, 2014, 9, e93321.	2.5	19
92	Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.. Journal of Clinical Oncology, 2014, 32, 3079-3079.	1.6	0
93	Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. Journal of Immunology, 2013, 190, 6034-6042.	0.8	145
94	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine, 2013, 19, 747-752.	30.7	979
95	Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood, 2013, 122, 1399-1410.	1.4	74
96	Autologous-collected anti-CD19 chimeric antigen receptor T cells (19CARTs) for pediatric acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL): Clinical activity and cytokine release without graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).. Journal of Clinical Oncology, 2013, 31, 10008-10008.	1.6	0
97	Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment. Journal of Immunotherapy, 2012, 35, 283-292.	2.4	114
98	Raising the Bar: The Curative Potential of Human Cancer Immunotherapy. Science Translational Medicine, 2012, 4, 127ps8.	12.4	218
99	Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8576-8576.	1.6	2
100	Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers.. Journal of Clinical Oncology, 2012, 30, e14179-e14179.	1.6	0
101	Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nature Reviews Clinical Oncology, 2011, 8, 577-585.	27.6	285
102	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research, 2011, 17, 4550-4557.	7.0	1,823
103	Personalized Cell Transfer Immunotherapy for B-Cell Malignancies and Solid Cancers. Molecular Therapy, 2011, 19, 1928-1930.	8.2	9
104	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research, 2011, 17, 5343-5352.	7.0	247
105	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology, 2011, 29, 917-924.	1.6	1,427
106	T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Molecular Therapy, 2011, 19, 620-626.	8.2	857
107	Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine. Journal of Immunotherapy, 2010, 33, 626-629.	2.4	24
108	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, 2010, 116, 3875-3886.	1.4	301

#	ARTICLE	IF	CITATIONS
109	CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 6122-6131.	7.0	269
110	Of Mice, Not Men: No Evidence for Graft-versus-Host Disease in Humans Receiving T-Cell Receptor-Transduced Autologous T Cells. <i>Molecular Therapy</i> , 2010, 18, 1744-1745.	8.2	67
111	Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. <i>Molecular Therapy</i> , 2010, 18, 843-851.	8.2	2,079
112	Adoptive cell therapy for the treatment of patients with metastatic melanoma. <i>Current Opinion in Immunology</i> , 2009, 21, 233-240.	5.5	539
113	Adoptive cell transfer: a clinical path to effective cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2008, 8, 299-308.	28.4	1,404
114	Overcoming obstacles to the effective immunotherapy of human cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12643-12644.	7.1	42
115	Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy. <i>Journal of Immunotherapy</i> , 2008, 31, 742-751.	2.4	236
116	Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor. <i>Blood</i> , 2008, 112, 4623-4623.	1.4	1
117	IL12 polarization of mouse and human T cells: implications for adoptive immunotherapy. <i>FASEB Journal</i> , 2008, 22, .	0.5	0
118	Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. <i>Science</i> , 2006, 314, 126-129.	12.6	2,352
119	IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells. <i>Journal of Immunotherapy</i> , 2006, 29, 313-319.	2.4	397
120	Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines. <i>Journal of Immunotherapy</i> , 2006, 29, 224-231.	2.4	31
121	Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy. <i>Journal of Immunotherapy</i> , 2005, 28, 53-62.	2.4	198
122	Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma. <i>Journal of Immunology</i> , 2005, 175, 6169-6176.	0.8	428
123	T Cells Associated with Tumor Regression Recognize Frameshifted Products of the <i>CDKN2A</i> Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product. <i>Journal of Immunology</i> , 2004, 172, 6057-6064.	0.8	114
124	Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy. <i>Journal of Immunology</i> , 2004, 173, 7125-7130.	0.8	442
125	Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14639-14645.	7.1	323
126	Reply to "Cancer vaccines: pessimism in check". <i>Nature Medicine</i> , 2004, 10, 1279-1280.	30.7	19

#	ARTICLE	IF	CITATIONS
127	Development of effective immunotherapy for the treatment of patients with cancer. Journal of the American College of Surgeons, 2004, 198, 685-696.	0.5	50
128	Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen. Human Gene Therapy, 2003, 14, 709-714.	2.7	105
129	Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients. Journal of Immunotherapy, 2003, 26, 332-342.	2.4	598
130	Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma. Journal of Immunotherapy, 2003, 26, 385-393.	2.4	58
131	Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clinical Cancer Research, 2003, 9, 2973-80.	7.0	82
132	Impact of the Number of Treatment Courses on the Clinical Response of Patients Who Receive High-Dose Bolus Interleukin-2. Journal of Clinical Oncology, 2000, 18, 1954-1959.	1.6	36
133	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. , 2000, 86, 818-826.		52
134	Expansion and Characterization of T Cells Transduced with a Chimeric Receptor against Ovarian Cancer. Human Gene Therapy, 2000, 11, 2377-2387.	2.7	54
135	Real-Time Quantitative Polymerase Chain Reaction Assessment of Immune Reactivity in Melanoma Patients After Tumor Peptide Vaccination. Journal of the National Cancer Institute, 2000, 92, 1336-1344.	6.3	102
136	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. International Journal of Cancer, 2000, 86, 818-826.	5.1	3
137	Identification of a Novel Major Histocompatibility Complex Class II-restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells. Journal of Experimental Medicine, 1999, 189, 1659-1668.	8.5	126
138	Human tumor antigens for cancer vaccine development. Immunological Reviews, 1999, 170, 85-100.	6.0	268
139	A new era of cancer immunotherapy: converting theory to performance. Ca-A Cancer Journal for Clinicians, 1999, 49, 70-73.	329.8	31
140	Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor Antigen. Science, 1999, 284, 1351-1354.	12.6	303
141	A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc- γ 3 chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nature Medicine, 1998, 4, 168-172.	30.7	63
142	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 1998, 4, 321-327.	30.7	1,693
143	Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer, 1998, 83, 797-805.	4.1	176
144	Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. , 1998, 75, 517-524.		160

#	ARTICLE	IF	CITATIONS
145	Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. <i>Annals of Surgical Oncology</i> , 1998, 5, 64-76.	1.5	30
146	Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. , 1998, 83, 797.		1
147	Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1595-1601.	6.3	145
148	Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use for Immuno-Gene Therapy. <i>International Reviews of Immunology</i> , 1997, 14, 173-192.	3.3	87
149	Human tumor antigens recognized by T-cells. <i>Immunologic Research</i> , 1997, 16, 313-339.	2.9	119
150	Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. <i>Journal of Leukocyte Biology</i> , 1996, 60, 296-309.	3.3	43
151	Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. <i>Annals of Surgical Oncology</i> , 1996, 3, 67-73.	1.5	12
152	T-cell recognition of self peptides as tumor rejection antigens. <i>Immunologic Research</i> , 1996, 15, 179-190.	2.9	53
153	The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. <i>Cancer</i> , 1995, 75, 1030-1037.	4.1	50
154	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. <i>Cancer</i> , 1995, 76, 687-694.	4.1	79
155	Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. <i>Nature Medicine</i> , 1995, 1, 330-336.	30.7	372
156	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. , 1995, 76, 687.		1
157	Localization of ¹¹¹ Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. <i>Cancer</i> , 1994, 73, 1731-1737.	4.1	204
158	Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. <i>Cancer</i> , 1994, 74, 3212-3222.	4.1	104
159	Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein-barr virus-transformed B cells. <i>International Journal of Cancer</i> , 1994, 58, 69-79.	5.1	78
160	Localization of ¹¹¹ Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. , 1994, 73, 1731.		1
161	Propagation of Mouse and Human T Cells with Defined Antigen Specificity and Function. <i>Novartis Foundation Symposium</i> , 1994, 187, 179-197.	1.1	4
162	Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 105-116.	4.2	4

#	ARTICLE	IF	CITATIONS
163	Regression of Metastatic Renal Cell Carcinoma After Cytoablative Nephrectomy. Journal of Urology, 1993, 150, 463-466.	0.4	132
164	Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer, 1992, 69, 1850-1855.	4.1	61
165	Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer, 1991, 68, 2384-2390.	4.1	75
166	Preparative Cytoablative Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. Journal of Urology, 1990, 144, 614-617.	0.4	90
167	Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer, 1990, 66, 1513-1516.	4.1	47
168	Extremity soft tissue sarcomas: Analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. Journal of Surgical Oncology, 1989, 41, 263-273.	1.7	61
169	Overview of interleukin-2 as an immunotherapeutic agent. Journal of Surgical Oncology, 1989, 5, 385-390.	1.4	41
170	In Vivo Distribution of Adoptively Transferred Indium- 111- Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients With Metastatic Melanoma. Journal of the National Cancer Institute, 1989, 81, 1709-1717.	6.3	176
171	Colonic perforation: An unusual complication of therapy with high-dose Interleukin-2. Cancer, 1988, 62, 2350-2353.	4.1	31
172	Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma. Clinical and Experimental Metastasis, 1988, 6, 387-400.	3.3	2
173	High-grade soft tissue sarcomas of the extremities. Cancer, 1986, 58, 190-205.	4.1	273
174	A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemotherapy and Pharmacology, 1986, 18, S25-S28.	2.3	59
175	A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer, 1985, 55, 1206-1214.	4.1	141
176	Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer, 1985, 55, 1327-1333.	4.1	125
177	Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer, 1985, 55, 1361-1366.	4.1	146
178	A Large Scale Method of Separating Multiple Lymphokines Secreted by the Murine EL-4 Thymoma. Immunopharmacology and Immunotoxicology, 1985, 7, 17-31.	0.8	2
179	Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer, 1984, 53, 896-905.	4.1	115
180	The significance of bone scan abnormalities in patients with primary osteogenic sarcoma. Journal of Surgical Oncology, 1984, 26, 122-129.	1.7	11

#	ARTICLE	IF	CITATIONS
181	Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer, 1983, 52, 424-434.	4.1	194
182	A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer, 1981, 47, 1746-1751.	4.1	76
183	The effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma. Cancer, 1981, 47, 2368-2374.	4.1	81
184	Evaluation of computed tomography in the detection of pulmonary metastases. A prospective study. Cancer, 1979, 43, 913-916.	4.1	173
185	Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer, 1979, 43, 2178-2181.	4.1	56
186	Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer, 1979, 44, 2291-2293.	4.1	51
187	Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate. Cancer, 1978, 41, 52-55.	4.1	54
188	Severe thrombocytopenia following intralesional BCG therapy. Cancer, 1978, 41, 820-826.	4.1	16
189	Clinical and immunologic studies of disseminated BCG infection. Cancer, 1978, 41, 1771-1780.	4.1	44
190	Clinical course and management of accidental adriamycin extravasation. Cancer, 1977, 40, 2053-2056.	4.1	119
191	Future prospects for immunotherapy. Cancer, 1975, 36, 821-824.	4.1	5